Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Depreciation & Amortization (CF) (2016 - 2024)

Historic Depreciation & Amortization (CF) for Alaunos Therapeutics (TCRT) over the last 14 years, with Q4 2024 value amounting to -$1000.0.

  • Alaunos Therapeutics' Depreciation & Amortization (CF) fell 10041.49% to -$1000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$1000.0, marking a year-over-year decrease of 10040.98%. This contributed to the annual value of $2000.0 for FY2024, which is 9991.36% down from last year.
  • Alaunos Therapeutics' Depreciation & Amortization (CF) amounted to -$1000.0 in Q4 2024, which was down 10041.49% from $1000.0 recorded in Q2 2024.
  • Alaunos Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $735000.0 during Q4 2022, with a 5-year trough of -$1000.0 in Q4 2024.
  • For the 5-year period, Alaunos Therapeutics' Depreciation & Amortization (CF) averaged around $465526.3, with its median value being $673000.0 (2021).
  • Per our database at Business Quant, Alaunos Therapeutics' Depreciation & Amortization (CF) surged by 28028.17% in 2021 and then crashed by 10041.49% in 2024.
  • Over the past 5 years, Alaunos Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $420000.0 in 2020, then soared by 68.57% to $708000.0 in 2021, then increased by 3.81% to $735000.0 in 2022, then tumbled by 67.21% to $241000.0 in 2023, then tumbled by 100.41% to -$1000.0 in 2024.
  • Its Depreciation & Amortization (CF) stands at -$1000.0 for Q4 2024, versus $1000.0 for Q2 2024 and $2000.0 for Q1 2024.